z-logo
Premium
Lipid‐Lowering Efficacy, Safety, and Costs of a Large‐Scale Therapeutic Statin Formulary Conversion Program
Author(s) -
Taylor Allen J.,
Grace Karen,
Swiecki Jennifer,
Hyatt Richard,
Gibbs Henry,
Sheikh Munazza,
O'Malley Patrick G.,
Lowenthal Susan Pitman,
West Mark,
Spain John,
Maneval Kent,
Jones David L.
Publication year - 2001
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.21.13.1130.34616
Subject(s) - formulary , medicine , adverse effect , observational study , statin , simvastatin , national cholesterol education program , cerivastatin , cholesterol , physical therapy , emergency medicine , pharmacology , pravastatin , obesity , metabolic syndrome
Study Objective. To assess the lipid‐lowering efficacy, safety, and costs of a large‐scale statin formulary conversion program. Design. Prospective, observational study. Setting. Tertiary academic medical center. Patients. A total of 980 patients consented to participate; 942 patients completed the study. Intervention. Patients were converted from their current statin therapy to either cerivastatin 0.4 or 0.8 mg/day, or simvastatin 80 mg/day, using a conversion algorithm. Measurements and Main Results. Efficacy and safety were evaluated at baseline and after 6 weeks of therapy; costs were also measured. Overall attainment of the National Cholesterol Education Program (NCEP) goal for low‐density lipoprotein cholesterol (LDL) increased from 64.8% to 74.5% of patients (p<0.001); mean LDL decreased from 115 ± 30 mg/dl to 106 ± 25 mg/dl (p<0.001). Adverse events occurred in 3% of patients, and included myositis (0.6%) and increased hepatic transaminases (0.1%). Overall costs were reduced by $115/patient treatment‐year. Conclusion. Statin therapeutic interchange can improve lipid control at reduced costs. The possibility of uncommon but potentially serious adverse effects suggests that these programs require appropriate monitoring.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here